PRELUDE CAPITAL MANAGEMENT, LLC

Position in NVAX — Novavax Inc

CIK 1387508 NEW YORK, NY

Back to NVAX Full portfolio

Position in NVAX

as of Jun 30, 2026 · filed Aug 14, 2026 Compact

Position Value

$191,226

+$68,071 QoQ

Shares Held

20,300

+5.7% QoQ

Ownership

0.012%

of shares outstanding

% of Portfolio

0.02%

of 13F equity value

Holder Rank

#134

of 263 holders

Holding Since

Mar 2020

8 quarters on record

Voting authority Sole 0% Shared 100% None 0%

Common Shares in NVAX Over Time

Shares Held

Position Value (USD)

Derivatives in NVAX

reported options exposure · as of Dec 31, 2021

CallValue

CallShares

PutValue

$1,158,867

PutShares

8,100

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

PRELUDE CAPITAL MANAGEMENT, LLC holds $41,687,806 across 71 Biotechnology names. NVAX ranks #35 (0.5% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	APGE	Apogee Therapeutics, Inc.	58,590	$7,776,650
2	TECH	BIO-TECHNE Corp	91,696	$6,478,322
3	PGEN	Precigen, Inc.	882,267	$5,028,921
4	ROIV	Roivant Sciences Ltd.	113,104	$4,002,750
5	RVMD	Revolution Medicines, Inc.	10,997	$2,059,518
6	QURE	uniQure N.V.	32,229	$1,484,467
7	MDXG	Mimedx Group, Inc.	215,239	$828,670
8	CGON	CG Oncology, Inc.	10,811	$768,121

All Filings in NVAX

Export CSV

8 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$191,226	20,300	+5.7%	Shares	Other	2026-08-14
2025-03-31	$123,155	19,213	—	Shares	Other	2025-05-15
2021-12-31	$1,158,867	8,100	0.0%	Put	Other	2022-02-14
2021-09-30	$1,679,211	8,100	+5.2%	Put	Sole	2021-11-15
2021-06-30	$1,634,787	7,700	0.0%	Put	Sole	2021-08-16
2021-03-31	$1,396,087	7,700	+67.4%	Put	Other	2021-05-17
2020-12-31	$512,946	4,600	—	Put	Other	2021-02-16
2020-03-31	$5,432	400	—	Call	Other	2020-05-15
No filing history on record for this holder in this stock.